Sunshine Biopharma Q1 EPS $(2.00) Misses $(1.04) Estimate, Sales $7.54M Beat $7.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sunshine Biopharma (NASDAQ:SBFM) reported Q1 earnings per share (EPS) of $(2.00), missing the analyst estimate of $(1.04) by 92.31%. However, the company reported sales of $7.54 million, beating the estimate of $7.00 million by 7.73%. Compared to the same period last year, EPS improved by 75% and sales increased by 54.08%.
May 21, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sunshine Biopharma reported a significant miss on Q1 EPS, coming in at $(2.00) versus the $(1.04) estimate, but showed strong sales performance with $7.54 million, beating the $7.00 million estimate. Despite the EPS miss, the YoY improvement in EPS and sales growth may provide some positive sentiment.
The significant miss on EPS is a negative factor, but the strong sales performance and YoY improvement in EPS may offset some of the negative sentiment. The mixed results are likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100